Polycystic Kidney Diseases
Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
Subtype terms (2)
More specific conditions that are subtypes of Polycystic Kidney Diseases in the MeSH hierarchy.
- Polycystic Kidney, Autosomal Dominant
57 drugs (32 approved, 25 experimental)
- Polycystic Kidney, Autosomal Recessive
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (12)
Phase 2 trials (3)
Phase 1 trials (1)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (32)
- Merck
- Genzyme
- Sanofi
- Ipsen
- Wyeth
- Reata Pharmaceuticals, Inc.
- Boehringer Ingelheim
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Aarhus University
- University of Pittsburgh
- Azienda Ospedaliero-Universitaria Consorziale
- Emory University
- Katholieke Universiteit Leuven
- Radboud University
- Seoul National University
- Tufts University
- University of Groningen
- Yale University
- University of Zurich
- Mayo Clinic
- University of Naples Frederico II
- University of Vienna
- Leiden University
- Hospital Alessandro Manzoni Lecco
- ASL Bari
- Mario Negri Institute
- Second Military Medical University
- University of Paris
- Erasmus University Rotterdam
- +2 more
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (2)